Tango-Revolution drug combination shows 82% response rate in advanced pancreatic cancer trial
An experimental drug combination from Tango Therapeutics and Revolution Medicines’ Rasonque produced tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, according to clinical trial results presented at ESMO in Madrid on…
